We are live on ! Find out more
ACHN

Achillion Pharmaceuticals
ACHN

Delisted

ACHN was delisted on the 27th of January, 2020.

Back to rankings

121 hedge funds and large institutions have $164M invested in Achillion Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 40 increasing their positions, 40 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

584% more call options, than puts

Call options by funds: $1.17M | Put options by funds: $171K

0% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 40

12% less funds holding

Funds holding: 137 → 121 (-16)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

58% less capital invested

Capital invested by funds: $394M → $164M (-$230M)

59% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 27

Holders
121
Holders Change
-16
Holders Change %
-11.68%
% of All Funds
2.7%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
11
Increased
40
Reduced
40
Closed
27
Calls
$1.17M
Puts
$171K
Net Calls
+$998K
Net Calls Change
+$625K

Top Buyers

Rank Fund Capital Flow
1
MCO
MAK Capital One
New York
+$9.17M
2
AC
Armistice Capital
New York
+$6.5M
3
UBS Group
UBS Group
Switzerland
+$3.71M
4
Citadel Advisors
Citadel Advisors
Florida
+$3.71M
5
Two Sigma Investments
Two Sigma Investments
New York
+$3.17M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$16.5M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$8.75M
3
NC
Nexthera Capital
New York
-$5.83M
4
EC
EcoR1 Capital
California
-$5.76M
5
BB
BB Biotech
Switzerland
-$4.71M
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$21.9M +$434K +153,679 +1%
BlackRock
2
BlackRock
New York
$19.2M +$497K +175,818 +1%
Vanguard Group
3
Vanguard Group
Pennsylvania
$13.7M -$8.75M -3,096,015 -26%
Dimensional Fund Advisors
4
Dimensional Fund Advisors
Texas
$11.8M +$734K +259,762 +4%
Citadel Advisors
5
Citadel Advisors
Florida
$8.72M +$3.71M +1,311,839 +31%
Goldman Sachs
6
Goldman Sachs
New York
$8.57M +$2.02M +713,201 +15%
MCO
7
MAK Capital One
New York
$8.26M +$9.17M +3,245,493 +167%
State Street
8
State Street
Massachusetts
$7.91M +$453K +160,408 +3%
AC
9
Armistice Capital
New York
$6.84M +$6.5M +2,300,000 +115%
RSCM
10
Rock Springs Capital Management
Maryland
$3.7M -$212K -75,000 -3%
Millennium Management
11
Millennium Management
New York
$3.31M +$1.97M +695,443 +50%
SDIC
12
South Dakota Investment Council
South Dakota
$2.94M +$1.87M +663,000 +56%
TA
13
Teachers Advisors
New York
$2.8M +$5.85K +2,070 +0.1%
Northern Trust
14
Northern Trust
Illinois
$2.57M -$37.7K -13,330 -0.8%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$2.46M +$258K +91,346 +6%
Man Group
16
Man Group
United Kingdom
$2.29M -$152K -53,651 -4%
UBS Group
17
UBS Group
Switzerland
$2.19M +$3.71M +1,312,467 +1,986%
OAM
18
Oxford Asset Management
United Kingdom
$2.09M +$2.01M +710,639 +118%
Two Sigma Investments
19
Two Sigma Investments
New York
$1.86M +$3.17M +1,122,993 +2,306%
Axa
20
Axa
France
$1.85M – – –
BBA
21
Baker Bros. Advisors
New York
$1.74M -$1.54M -544,589 -33%
6CM
22
683 Capital Management
New York
$1.59M +$2.83M +1,000,000 New
JP Morgan Chase
23
JP Morgan Chase
New York
$1.58M -$132K -46,724 -4%
Renaissance Technologies
24
Renaissance Technologies
New York
$1.48M +$2.29M +809,100 +659%
PAM
25
Panagora Asset Management
Massachusetts
$1.44M -$117K -41,351 -4%
1
2 3 4 5

ACHN Hedge Fund Activity: Q4 2018 in Review

121 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q4 2018, worth a combined $164M — down 58% from $394M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of ACHN and 11 opened new positions — a net loss of 16 holders — while 40 trimmed existing stakes and 40 added.

The largest buyer was MAK Capital One, adding an estimated $9.17M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $16.5M sold.

  • 121 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q4 2018, down from 137 in Q3 2018.
  • Funds reported $164M of Achillion Pharmaceuticals stock for Q4 2018, down 58% quarter-over-quarter.
  • 11 funds opened new Achillion Pharmaceuticals positions in Q4 2018 and 27 closed out, a net change of -16 holders.
  • The largest Achillion Pharmaceuticals buyer in Q4 2018 was MAK Capital One, an estimated $9.17M added.
  • The largest Achillion Pharmaceuticals seller in Q4 2018 was T. Rowe Price Associates, an estimated $16.5M sold.

Based on aggregated 13F filings for Q4 2018.